CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-09-07): Hemochromatosis no barrier to successful liver transplantation

Clinical

Hemochromatosis no barrier to successful liver transplantation

Last Updated: 2007-09-07 20:03:28 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Over the last decade, patients with hemochromatosis did as well or better after liver transplantation than those without the iron overload disease, two physicians-researchers report in the August issue of Gastroenterology.

Historically, patients with hemochromatosis did not fare well after undergoing liver transplantation, Dr. Lei Yu and Dr. George N. Ioannou explain. They speculated that advances in patient care and better patient selection may have improved their outlook.

To explore these issues, Dr. Yu and Dr. Ioannou, at the University of Washington in Seattle, obtained records from the United Network for Organ Sharing for liver transplantations performed in the US. They compared outcomes among patients with hemochromatosis who received a liver transplant between 1990 and 1996 versus those who underwent transplantation between 1997 and 2006.

Included were 177 (1.1%) patients with hemochromatosis before 1997 and 217 (0.06%) afterward. Patients without hemochromatosis totaled 16,109 and 33,803, respectively.

During the initial study period, post-transplant survival was worse than that of patients without hemochromatosis. The 5-year survival was 64.6% among those with hemochromatosis and 73.8% for the rest of the patients.

"Recipients with hemochromatosis had the worst post-transplantation survival of any other recipient group defined by cause of liver disease other than hepatocellular carcinoma," the results show.

During the recent period, outcomes were "excellent" for patients with hemochromatosis, Drs. Yu and Ioannou report. Five-year survival was 77.3% for patients with hemochromatosis versus 74.0% for those with other indications for the procedure.

In fact, the survival among hemochromatosis patients was "superior to not only recipients with hepatocellular carcinoma but also those with hepatitis C infection, nonalcoholic steatohepatitis or cryptogenic cirrhosis, alcoholic liver disease or acute hepatic failure."

The authors suggest that more stringent exclusion of patients with cardiac disease and improved patient care may have affected outcomes after receiving a liver transplant.

Gastroenterology 2007;133:489-495.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.